SCHEMBL19975259

SCHEMBL19975259

CCOC(=O)C(O)C(CC)N(C=O)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 3/20 0.38
CTDSP1 Q9GZU7 1/20 0.38
TSHR P16473 1/20 0.38
MMP8 P22894 2/20 0.38
TDP1 Q9NUW8 1/20 0.37
POLB P06746 2/20 0.36
HSD17B10 Q99714 2/20 0.36
LMNA P02545 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CYP1A2 P05177 1/20 0.36
MAPT P10636 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19975386 0.89 POLB (0.43) PIN1SMN1; SMN2MEN1KMT2ANPC1
SCHEMBL19975026 0.86 PIN1 (0.42) PIN1SMN1; SMN2MEN1KMT2ANPC1
SCHEMBL5777177 0.77 PIN1 (0.42) PIN1SMN1; SMN2MEN1KMT2ANPC1
SCHEMBL19975442 0.76 PKM (0.41) SMN1; SMN2MEN1KMT2APOLBLMNA
SCHEMBL25375693 0.75 SMN1; SMN2 (0.43) PIN1SMN1; SMN2MEN1KMT2ANPC1
SCHEMBL19975370 0.75 PTGIR (0.40) ALDH1A1CYP2C19
SCHEMBL19975122 0.69 ALDH1A1 (0.40) SMN1; SMN2MEN1KMT2AALDH1A1TSHR
SCHEMBL11550667 0.69 ALDH1A1 (0.41) SMN1; SMN2MEN1KMT2AALDH1A1TSHR
SCHEMBL10524958 0.68 PIN1 (0.47) PIN1SMN1; SMN2MEN1KMT2ANPC1
SCHEMBL31016233 0.68 KMT2A (0.50) SMN1; SMN2MEN1KMT2ATSHRL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C PIN1 3917/4885SMN1; SMN2 706/4885MEN1 4331/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C PIN1 3952/4885SMN1; SMN2 1086/4885MEN1 4361/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C PIN1 3917/4885SMN1; SMN2 706/4885MEN1 4331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.